EUSA Pharma launches phase III COVID-19 study for siltuximab
Study will enrol hospitalised COVID-19 patients with serious viral acute respiratory distress syndrome
Read More
Tag: siltuximab
EUSA Pharma bags US approval for COVID-19 trial
Siltuximab is a monoclonal antibody that directly neutralises interleukin (IL)-6, an inflammatory cytokine
Read More
Positive early data from siltuximab COVID-19 trial
One-third (33%) of patients experienced a clinical improvement with a reduced need for oxygen support
Read More
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
